Best objective clinical responses from screening to week 26
| . | 300 mg . | 500 mg . | 700 mg . | 1000 mg . | Total . |
|---|---|---|---|---|---|
| No. of patients (all/previously treated with rituximab) | 8*/4* | 10†/2 | 10/3 | 10/5 | 38†/14 |
| CR | 4/3 | 1/0 | 5/3 | ||
| Cru | 1/1 | 1/0 | 2/1 | ||
| PR | 2/0 | 2/1 | 5/4 | 9/5 | |
| SD | 3/0 | 6/2 | 6/1 | 3/1 | 18/4 |
| PD | 2/1 | 1/0 | 3/1 | ||
| Clinical response (all/previously treated with rituximab) | 5/4 | 3/0 | 2/1 | 6/4 | 16/9 |
| Evaluable patients | 63% | 33% | 20% | 60% | 43% |
| 95% CI | (25%-92%) | (8%-70%) | (3%-56%) | (26%-88%) | (27%-61%) |
| Intention to treat (ITT) | 63% | 30% | 20% | 60% | 42% |
| 95% CI | (25%-92%) | (7%-65%) | (3%-56%) | (26%-88%) | (26%-59%) |
| Patients previously treated with rituximab | 100% | 0% | 33% | 80% | 64% |
| 95% CI | (40%-100%) | (1%-91%) | (28%-100%) | (43%-95%) |
| . | 300 mg . | 500 mg . | 700 mg . | 1000 mg . | Total . |
|---|---|---|---|---|---|
| No. of patients (all/previously treated with rituximab) | 8*/4* | 10†/2 | 10/3 | 10/5 | 38†/14 |
| CR | 4/3 | 1/0 | 5/3 | ||
| Cru | 1/1 | 1/0 | 2/1 | ||
| PR | 2/0 | 2/1 | 5/4 | 9/5 | |
| SD | 3/0 | 6/2 | 6/1 | 3/1 | 18/4 |
| PD | 2/1 | 1/0 | 3/1 | ||
| Clinical response (all/previously treated with rituximab) | 5/4 | 3/0 | 2/1 | 6/4 | 16/9 |
| Evaluable patients | 63% | 33% | 20% | 60% | 43% |
| 95% CI | (25%-92%) | (8%-70%) | (3%-56%) | (26%-88%) | (27%-61%) |
| Intention to treat (ITT) | 63% | 30% | 20% | 60% | 42% |
| 95% CI | (25%-92%) | (7%-65%) | (3%-56%) | (26%-88%) | (26%-59%) |
| Patients previously treated with rituximab | 100% | 0% | 33% | 80% | 64% |
| 95% CI | (40%-100%) | (1%-91%) | (28%-100%) | (43%-95%) |